CLT1 targets bladder cancer through integrin α5β1 and CLIC3

Molecular Cancer Research

Volumn 11, Issue 2, 2013, Pages 194-203

  Knowles, Lynn M ^a   Zewe, James ^a   Malik, Gunjan ^a   Parwani, Anil V ^b,c   Gingrich, Jeffrey R ^a,c   Pilch, Jan ^a,c  

^a Departments of Urology   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CHLORIDE INTRACELLULAR CHANNEL 1 PROTEIN; CHLORIDE INTRACELLULAR CHANNEL 3 PROTEIN; FIBRONECTIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; BLADDER CANCER; BREAST CANCER; CELL DIFFERENTIATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; KIDNEY CANCER; LUNG CANCER; MICROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

AUTOPHAGY; CELL LINE, TUMOR; FIBRONECTINS; GENE SILENCING; HUMANS; INTEGRIN ALPHA5BETA1; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDES, CYCLIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84874399556     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0300     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Falke J, Witjes JA. Perioperative management of nonmuscle-invasive bladder cancer. Curr Opin Urol 2011;21:403-8.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-5; discussion 475-7.
4. Weizer AZ, Tallman C, Montgomery JS. Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. World J Urol 2011;29:59-71.
5. Brassell SA, Kamat AM. Contemporary intravesical treatment options for urothelial carcinoma of the bladder. J Natl Compr Cancer Netw 2006;4:1027-36.
6. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011;186:2158-67.
7. Gingrich Jr. Bladder cancer: Chemohyperthermia for bladder cancerclinically effective? Nat Rev Urol 2011;8:414-6.
8. Moses KA, Zhang J, Hricak H, Bochner BH. Bladder cancer imaging: An update. Curr Opin Urol 2011;21:393-7.
9. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-14.
10. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-30.
11. Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010;57:60-70.
12. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86-91; discussion 92.
13. Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006;175:2004-10.
14. Sylvester RJ. Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer. Int J Urol 2011;18:113-20.
15. Rosevear HM, Lightfoot AJ, O'Donnell MA, Griffith TS. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev 2009;28:345-53.
16. Pilch J, Brown DM, Komatsu M, Jarvinen TA, Yang M, Peters D, et al. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci U S A 2006;103:2800-4.
17. Knowles LM, Malik G, Hood BL, Conrads TP, Pilch J. CLT1 targets angiogenic endothelium through CLIC1 and fibronectin. Angiogenesis 2012;15:115-29.
18. Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL. Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 1993;91:69-76.
19. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 1990;85:62-7.
20. Ruoslahti E. The Walter Herbert Lecture. Control of cell motility and tumour invasion by extracellular matrix interactions. Br J Cancer 1992;66:239-42.
21. Dozynkiewicz MA, Jamieson NB, Macpherson I, Grindlay J, van den Berghe PV, von Thun A, et al. Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Dev Cell 2012;22:131-45.
22. Pilewski JM, Latoche JD, Arcasoy SM, Albelda SM. Expression of integrin cell adhesion receptors during human airway epithelial repair in vivo. Am J Physiol 1997;273:L256-63.
23. Saito T, Kimura M, Kawasaki T, Sato S, Tomita Y. Correlation between integrin alpha 5 expression and the malignant phenotype of transitional cell carcinoma. Br J Cancer 1996;73:327-31.
24. Woodward TL, Mienaltowski AS, Modi RR, Bennett JM, Haslam SZ. Fibronectin and the alpha(5)beta(1) integrin are under developmental and ovarian steroid regulation in the normal mouse mammary gland. Endocrinology 2001;142:3214-22.
25. WuXR. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 2005;5:713-25.
26. van der Horst G, Bos L, van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res 2012;10:995-1009.
27. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res 1999;76:1-20.
28. Caswell PT, Vadrevu S, Norman JC. Integrins: Masters and slaves of endocytic transport. Nat Rev Mol Cell Biol 2009;10:843-53.
29. Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 2005;95: 655-9.
30. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 2012;18:1323-33.
31. Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci 2002;115: 3861-3.
32. Lobert VH, Brech A, Pedersen NM, Wesche J, Oppelt A, Malerod L, et al. Ubiquitination of alpha 5 beta 1 integrin controls fibroblast migration through lysosomal degradation of fibronectin-integrin complexes. Dev Cell 2010;19:148-59.
33. Littler DR, Brown LJ, Breit SN, Perrakis A, Curmi PM. Structure of human CLIC3 at 2 A resolution. Proteins 2010;78:1594-600.
34. Zullo AJ, Lee S. Mycobacterial induction of autophagy varies by species and occurs independently of mTOR inhibition. J Biol Chem 2012;287:12668-78.
35. Chen F, Zhang G, Cao Y, Payne R, See WA. Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury. J Urol 2007;178:2166-70.